Lithium Trial in Alzheimer's Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study
Lithium Trial in Alzheimer's Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study
复制标题
DOI：
10.4088/jcp.08m04606
复制
发表时间：
2009-06-01
影响因子：
5.3
通讯作者：
Basun, Hans
中科院分区：
文献类型：
--
作者：
Hampel, Harald;Ewers, Michael;Basun, Hans
目的：锂是治疗双相抑郁症的一线药物，最近已被证明可以调节糖原合成酶激酶-3（GSK-3），这是一种参与tau蛋白磷酸化的激酶。由于tau蛋白的过度磷酸化是阿尔茨海默病的核心病理特征，锂诱导的GSK-3活性抑制可能对阿尔茨海默病具有治疗作用。在本研究中，我们测试了短期锂治疗对阿尔茨海默病患者的影响。方法：共有71例轻度阿尔茨海默病患者（简易精神状态检查评分>= 21，
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer's disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in Alzheimer's disease. In the current study, we tested the effect of short-term lithium treatment in patients with Alzheimer's disease.Method: A total of 71 patients with mild Alzheimer's disease (Mini-Mental State Examination score >= 21 and